查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085417

隱球菌病市場：按藥物類別、適應症、給藥途徑、最終用戶和分銷管道分類的全球市場預測，2026-2032 年

Cryptococcosis Market by Drug Class, Indication, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，隱球菌病市場規模將成長至 94.9 億美元，複合年成長率為 4.72%。

主要市場統計數據
基準年 2025 68.7億美元
預計年份：2026年 71.8億美元
預測年份 2032 94.9億美元
複合年成長率 (%) 4.72%

隱球菌病市場概覽

隱球菌病是嚴重的侵襲性真菌感染疾病，主要由新型隱球菌和格特隱球菌引起，其中隱球菌性腦膜炎是最致命的臨床表現。此病的高發生率包括晚期HIV感染疾病者、器官移植受者、接受免疫抑制治療的患者、惡性腫瘤患者等免疫力缺乏族群。

隱球菌病現狀的變革性變化

目前隱球菌病的治療模式正從醫院的被動治療轉向對高風險族群的早期篩檢。世界健康組織建議對晚期HIV感染疾病患者，尤其是CD4細胞計數低的患者進行隱球菌莢膜抗原（CrAg）篩檢。這是因為抗原血症可能領先腦膜炎發生，為預防性抗真菌治療提供了機會。

人工智慧（AI）的累積影響

人工智慧 (AI) 正透過風險分層、臨床決策支援、實驗室工作流程自動化和監測分析等方式，開始影響隱球菌病的管理。 AI 模型可以幫助識別那些錯過了 CD4 檢測、隱球菌莢膜抗原 (CrAg)篩檢、腰椎穿刺評估或抗真菌藥物治療後追蹤的進行性HIV感染疾病患者。

按地區分類的主要發現

亞太地區隱球菌病管理有顯著差異，這主要是由於該地區免疫力缺乏人群眾多，且醫療資源取得程度參差不齊。儘管中國、印度、日本、韓國和澳洲擁有完善的三級醫療體系，但在真菌感染疾病的早期診斷方面仍存在差距。同時，東南亞國協面臨更大的壓力，需要擴大隱球菌莢膜抗原（CrAg）篩檢範圍，完善實驗室轉診系統，並確保患者能夠獲得價格合理的抗真菌藥物。印度和中國的情況尤其重要，兩國愛滋病、癌症、器官移植和慢性病的發生率較高，凸顯了建立可擴展的隱球菌病診斷和治療路徑的迫切需求。

主要市場趨勢

東協市場格局受多種因素影響，包括與愛滋病預防計畫的整合、公共檢測實驗室能力的差異，以及在地方和地區級醫療機構附近開展即時隱球菌抗原（CrAg）檢測的機會。該地區各國迫切需要協調篩檢和確診、抗真菌藥物採購以及臨床醫生培訓，以便隱球菌抗原陽性結果能夠及時得到預防性治療和腦膜炎管理。

主要國家的概況

美國和加拿大擁有完善的診斷和專科醫療保健體系，其需求主要集中在愛滋病治療、器官移植、腫瘤治療、風濕病相關免​​疫抑制治療和重症監護方面。墨西哥和巴西則面臨雙重需求：一方面需要先進的醫院管理，另一方面需要更廣泛地提供快速診斷服務。尤其值得一提的是，降低隱球菌腦膜炎的死亡率需要公共衛生系統協調愛滋病防治計畫、轉診醫院和抗真菌藥物供應鏈。

為行業領導者提供的實用建議

行業領導者應優先考慮以可及性為導向的策略，使診斷和治療的可及性保持一致。在缺乏可靠的抗真菌藥物供應鏈的情況下，擴大對隱球菌曲霉複合體 (CrAg) 的篩檢將收效甚微。因此，建構包含快速檢測、確診試劑、Amphotericin B製劑、Flucytosine和Fluconazole在內的協調產品系列，將創造更大的公共衛生價值。

調查方法

本執行摘要採用系統性的二手研究途徑編寫，依據世界衛生組織、美國疾病管制與預防中心、聯合國愛滋病規劃署和各國衛生組織公開的指南和監測數據，以及同行評審的感染疾病文獻和臨床實踐指南。本分析重點檢驗的疾病負擔、診斷途徑、治療建議、就醫限制以及目前的醫療服務狀況。

結論

隱球菌病市場有明確的臨床需求：早期發現並迅速獲得有效的抗真菌治療可以降低隱球菌性腦膜炎的死亡率。診斷方法的多樣化、治療方案的最佳化、腰椎穿刺的實施以及與愛滋病和免疫力缺乏患者的護理路徑相結合，仍然是最重要的成長要素。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 隱球菌病市場：依藥物類別分類

  • 唑類藥物
    • Fluconazole
    • Isavuconazole
    • Itraconazole
    • Posaconazole
    • Voriconazole
  • 棘白菌素類
    • 安杜拉真菌
    • 卡斯波方金
    • Micafungin
  • Polyenes
  • 嘧啶類似物

第8章：隱球菌病市場：依適應症分類

  • 隱球菌性腦膜炎
  • 播散性隱球菌病
  • 肺隱球菌病

第9章：隱球菌病市場：依給藥途徑分類

  • 靜脈
  • 口服

第10章：隱球菌病市場：依最終用戶分類

  • 門診部
  • 診所
  • 醫院

第11章：隱球菌病市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 隱球菌病市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 隱球菌病市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 隱球菌病市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • BM Pharmaceuticals
  • Bausch Health Companies Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Citron Pharma
  • Eisai Co., Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Johnson & Johnson Services, Inc.
  • Jolly Limited
  • Lunan Pharmaceutical Group
  • Matinas Biopharma Holdings, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • NuCare Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Sigmapharm Laboratories, LLC
  • Skyepharma Production SAS
  • Sumitomo Pharma Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-4348D129F9A0

The Cryptococcosis Market is projected to grow by USD 9.49 billion at a CAGR of 4.72% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.87 billion
Estimated Year [2026] USD 7.18 billion
Forecast Year [2032] USD 9.49 billion
CAGR (%) 4.72%

Cryptococcosis Market Introduction

Cryptococcosis is a serious invasive fungal disease caused primarily by Cryptococcus neoformans and Cryptococcus gattii, with cryptococcal meningitis representing the highest-mortality presentation. The disease burden is concentrated among people with advanced HIV disease, transplant recipients, patients receiving immunosuppressive therapies, malignancy patients, and other immunocompromised populations.

WHO and CDC guidance position cryptococcal antigen (CrAg) screening, rapid diagnosis, and timely antifungal treatment as central to reducing mortality. For the cryptococcosis market, growth is shaped by demand for CrAg lateral flow assays, cerebrospinal fluid diagnostics, fungal culture, amphotericin B formulations, flucytosine access, fluconazole maintenance therapy, and integrated HIV care pathways.

Transformative Shifts in the Cryptococcosis Landscape

The cryptococcosis landscape is shifting from reactive hospital-based treatment toward earlier detection in high-risk populations. WHO recommends CrAg screening for people with advanced HIV disease, particularly those with low CD4 counts, because antigenemia can precede meningitis and create an opportunity for pre-emptive antifungal therapy.

Treatment standards are also evolving. WHO guidance supports optimized induction regimens, including liposomal amphotericin B-based approaches where available, alongside flucytosine and fluconazole. Market transformation is therefore tied to affordability, supply reliability, clinical training, lumbar puncture capacity, therapeutic monitoring, and diagnostic decentralization in countries with the highest HIV-associated disease burden.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence cryptococcosis care through risk stratification, clinical decision support, laboratory workflow automation, and surveillance analytics. AI models can help identify patients with advanced HIV disease who are overdue for CD4 testing, CrAg screening, lumbar puncture evaluation, or follow-up after antifungal initiation.

The near-term value of AI is operational rather than substitutive. Algorithms can flag abnormal laboratory patterns, support antifungal stewardship, analyze imaging when pulmonary or central nervous system disease is suspected, and improve outbreak or cluster detection. However, AI adoption must be validated locally and integrated with clinician-led diagnosis, confirmatory testing, ethics safeguards, data quality controls, and pharmacovigilance.

Key Regional Insights

Asia-Pacific contains large immunocompromised populations and diverse healthcare access levels, making cryptococcosis management highly variable. China, India, Japan, South Korea, and Australia combine advanced tertiary care capacity with persistent gaps in early fungal diagnosis, while ASEAN countries face stronger pressure to expand CrAg screening, laboratory referral systems, and affordable antifungal availability. India and China are particularly important because large HIV, oncology, transplant, and chronic disease populations increase the need for scalable cryptococcosis diagnostics and treatment pathways.

North America benefits from established infectious disease networks, transplant programs, fungal reference laboratories, and access to advanced antifungal formulations, with demand concentrated in HIV care, oncology, critical care, and post-transplant management. Europe shows similar strengths through guideline-based care, antifungal stewardship, and structured hospital diagnostics, although country-level differences remain in reimbursement and access to specialized mycology testing.

Latin America demonstrates rising awareness of invasive fungal disease but continues to face uneven access to rapid diagnostics, flucytosine, and advanced amphotericin B formulations across public healthcare systems. The Middle East shows demand linked to tertiary hospitals, transplant services, oncology care, and expatriate populations, with procurement often focused on reliable diagnostic quality and specialist hospital treatment. Africa remains especially important because HIV-associated cryptococcal meningitis continues to drive preventable mortality where CrAg screening, lumbar puncture access, flucytosine, amphotericin B supply, and follow-up systems are inconsistent.

Key Group Insights

ASEAN markets are shaped by HIV program integration, variable public laboratory capacity, and opportunities to deploy point-of-care CrAg testing closer to community and district-level care. Countries across the bloc face a practical need to link screening with confirmatory assessment, antifungal procurement, and clinician training so that cryptococcal antigen positivity translates into timely pre-emptive therapy or meningitis management.

The GCC shows demand linked to tertiary hospitals, transplant services, oncology care, and care for expatriate populations, with procurement often focused on high-quality diagnostics and advanced antifungal therapies. The European Union and G7 countries prioritize guideline-based care, reimbursement, antifungal stewardship, surveillance of invasive fungal infections, and resilient hospital supply chains that support access to CrAg testing, lumbar puncture-based diagnosis, and induction therapy.

BRICS nations represent substantial strategic relevance due to large populations, expanding healthcare systems, rising transplant and oncology care, and continuing HIV-associated cryptococcosis needs in several member countries. NATO countries overlap with many high-income markets where preparedness, military health systems, cross-border procurement coordination, and secure medical supply chains influence diagnostic and antifungal availability for severe fungal infections.

Key Country Insights

The United States and Canada have strong diagnostic and specialist care capacity, with demand concentrated in HIV care, transplant medicine, oncology, rheumatology-associated immunosuppression, and critical care. Mexico and Brazil face dual needs for advanced hospital management and broader access to rapid diagnostics, particularly where public health systems must connect HIV programs, referral hospitals, and antifungal supply chains to reduce cryptococcal meningitis mortality.

The United Kingdom, Germany, France, Italy, and Spain benefit from structured infectious disease services, hospital mycology expertise, reimbursement frameworks, and antifungal stewardship programs that support appropriate testing and treatment. Russia presents demand across HIV care and hospital-based immunocompromised populations, where earlier recognition, laboratory capacity, and reliable antifungal access remain important to improving cryptococcosis outcomes.

China and India are central to long-term market expansion because of large patient bases, improving laboratory networks, broader hospital modernization, and increasing awareness of invasive fungal disease among HIV, oncology, and transplant populations. Japan, Australia, and South Korea have mature hospital systems and strong diagnostic adoption potential, supporting demand for high-quality CrAg testing, fungal culture, molecular tools, imaging-supported assessment, and safer antifungal regimens.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize access-oriented strategies that align diagnostics with treatment availability. Expanding CrAg screening without reliable antifungal supply limits clinical impact; therefore, coordinated portfolios that include rapid tests, confirmatory diagnostics, amphotericin B formulations, flucytosine, and fluconazole can create stronger public health value.

Manufacturers, distributors, and healthcare partners should invest in clinician education, laboratory quality assurance, cold-chain and stockout mitigation, pharmacovigilance, and evidence generation in high-burden settings. Partnerships with HIV programs, transplant centers, oncology networks, public laboratories, and global health agencies can accelerate adoption while supporting measurable reductions in cryptococcal meningitis mortality.

Research Methodology

This executive summary is developed using a structured secondary research approach grounded in publicly available guidance and surveillance from WHO, CDC, UNAIDS, national health agencies, peer-reviewed infectious disease literature, and clinical practice guidelines. The analysis emphasizes verified disease burden, diagnostic pathways, treatment recommendations, access constraints, and healthcare delivery realities.

Market interpretation combines epidemiological relevance, healthcare infrastructure assessment, product adoption dynamics, procurement patterns, regional policy context, and clinical pathway analysis. Insights are synthesized to support strategic decision-making across diagnostics, antifungal therapy, hospital care, HIV programs, transplant medicine, oncology care, and public health interventions without relying on unverified market-size claims.

Conclusion

The cryptococcosis market is defined by a clear clinical imperative: earlier detection and faster access to effective antifungal therapy can reduce deaths from cryptococcal meningitis. Diagnostic decentralization, treatment optimization, lumbar puncture capacity, and integration with HIV and immunocompromised care pathways remain the most important growth drivers.

Future competitiveness will depend on evidence-based product positioning, affordability, supply continuity, quality assurance, and partnerships that close gaps between screening and treatment. Organizations that combine clinical credibility with access-focused execution are best positioned to create durable impact in cryptococcosis care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cryptococcosis Market, by Drug Class

  • 7.1. Azoles
    • 7.1.1. Fluconazole
    • 7.1.2. Isavuconazole
    • 7.1.3. Itraconazole
    • 7.1.4. Posaconazole
    • 7.1.5. Voriconazole
  • 7.2. Echinocandins
    • 7.2.1. Anidulafungin
    • 7.2.2. Caspofungin
    • 7.2.3. Micafungin
  • 7.3. Polyenes
  • 7.4. Pyrimidine Analogues

8. Cryptococcosis Market, by Indication

  • 8.1. Cryptococcal Meningitis
  • 8.2. Disseminated Cryptococcosis
  • 8.3. Pulmonary Cryptococcosis

9. Cryptococcosis Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral

10. Cryptococcosis Market, by End User

  • 10.1. Ambulatory Care Center
  • 10.2. Clinic
  • 10.3. Hospital

11. Cryptococcosis Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Cryptococcosis Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Cryptococcosis Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cryptococcosis Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. Astellas Pharma Inc.
  • 16.3. B.M. Pharmaceuticals
  • 16.4. Bausch Health Companies Inc.
  • 16.5. Bayer AG
  • 16.6. Bristol-Myers Squibb Company
  • 16.7. Citron Pharma
  • 16.8. Eisai Co., Ltd.
  • 16.9. Gilead Sciences, Inc.
  • 16.10. GlaxoSmithKline PLC
  • 16.11. Glenmark Pharmaceuticals Limited
  • 16.12. Johnson & Johnson Services, Inc.
  • 16.13. Jolly Limited
  • 16.14. Lunan Pharmaceutical Group
  • 16.15. Matinas Biopharma Holdings, Inc.
  • 16.16. Merck & Co., Inc.
  • 16.17. Novartis AG
  • 16.18. NuCare Pharmaceuticals, Inc.
  • 16.19. Pfizer Inc.
  • 16.20. Sanofi S.A.
  • 16.21. Sigmapharm Laboratories, LLC
  • 16.22. Skyepharma Production SAS
  • 16.23. Sumitomo Pharma Co., Ltd.
  • 16.24. Takeda Pharmaceutical Company Limited
  • 16.25. Teva Pharmaceutical Industries Ltd.
  • 16.26. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CRYPTOCOCCOSIS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CRYPTOCOCCOSIS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CRYPTOCOCCOSIS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CRYPTOCOCCOSIS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CRYPTOCOCCOSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL CRYPTOCOCCOSIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AZOLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AZOLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AZOLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FLUCONAZOLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FLUCONAZOLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FLUCONAZOLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ISAVUCONAZOLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ISAVUCONAZOLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ISAVUCONAZOLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ITRACONAZOLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ITRACONAZOLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ITRACONAZOLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL POSACONAZOLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL POSACONAZOLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL POSACONAZOLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VORICONAZOLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VORICONAZOLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VORICONAZOLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ECHINOCANDINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ECHINOCANDINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ECHINOCANDINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANIDULAFUNGIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIDULAFUNGIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANIDULAFUNGIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CASPOFUNGIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CASPOFUNGIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CASPOFUNGIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MICAFUNGIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MICAFUNGIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MICAFUNGIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POLYENES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL POLYENES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL POLYENES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PYRIMIDINE ANALOGUES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PYRIMIDINE ANALOGUES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PYRIMIDINE ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CRYPTOCOCCAL MENINGITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CRYPTOCOCCAL MENINGITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CRYPTOCOCCAL MENINGITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DISSEMINATED CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DISSEMINATED CRYPTOCOCCOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DISSEMINATED CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PULMONARY CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PULMONARY CRYPTOCOCCOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PULMONARY CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AMBULATORY CARE CENTER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AMBULATORY CARE CENTER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AMBULATORY CARE CENTER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CLINIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CLINIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CLINIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. GCC CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 135. GCC CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. GCC CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 137. GCC CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 138. GCC CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. GCC CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. GCC CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. GCC CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. G7 CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. G7 CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 160. G7 CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 161. G7 CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 162. G7 CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 163. G7 CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. G7 CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. G7 CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. NATO CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. NATO CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 168. NATO CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 169. NATO CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 170. NATO CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 171. NATO CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. NATO CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. NATO CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. CANADA CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 185. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 186. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 187. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 188. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. MEXICO CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 193. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 194. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 195. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 201. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 202. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 203. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 204. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. GERMANY CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 216. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 217. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 218. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 219. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 220. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. FRANCE CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 225. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 226. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 227. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 228. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 232. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 233. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 234. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 235. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 236. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. ITALY CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 241. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 242. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 243. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 244. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 245. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. SPAIN CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 249. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 250. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 251. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 252. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 253. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. INDIA CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 265. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 266. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 267. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 268. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 269. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. JAPAN CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 273. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 274. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 275. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 276. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 277. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 279. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 280. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 281. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 282. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 283. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 284. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 285. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 288. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 289. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 290. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY ECHINOCANDINS, 2018-2032 (USD MILLION)
  • TABLE 291. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 292. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 293. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)